Cancer drug snub wipes £3bn off GSK value
GSK was trying to revive a product pulled from US markets in 2022. Its shares fell 4.6 per cent, or 65p, to 1348p.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.